Over 150 Total Lots Up For Auction at Two Locations - PA 05/15, NY 05/20

Physician burnout costs the US health care system approximately $4.6 billion a year

Press releases may be edited for formatting or style | May 29, 2019

Maintaining a healthy lifestyle over the lifespan.
Use of maximally tolerated doses of statins in secondary prevention of ASCVD
Use of nonstatin medications in addition to statin therapy for patients at very high risk for ASCVD.
Use of statin therapy without risk stratification in severe primary hypercholesterolemia, often starting in childhood.
stats
DOTmed text ad

We repair MRI Coils, RF amplifiers, Gradient Amplifiers and Injectors.

MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013

stats

Use of moderate-intensity statin therapy without risk stratification in adults aged 40 to 75 years with diabetes mellitus and an LDL-C level of 1.8 mmol/L (70 mg/dL) or higher.
Clinician-patient risk discussion about statin therapy for adults aged 40 to 75 years without diabetes mellitus who have LDL-C levels of at least 1.8 mmol/L (70 mg/dL), and a 10-year ASCVD risk of 7.5% or higher.
Use of moderate-intensity statin therapy if a risk discussion favors their use in adults aged 40 to 75 years without diabetes mellitus who have LDL-C levels of at least 1.8 mmol/L (70 mg/dL), and a 10-year ASCVD risk of 7.5% or higher.
Use of a 3-tiered decision-making process in primary prevention in adults aged 40 to 75 years to personalize the risk decision. This includes enhancing factors such as family history of premature CAD, metabolic syndrome, chronic kidney disease, LDL-cholesterol level ?160 mg/dL; in women, history of pre-eclampsia or premature menopause (<40 y); inflammatory diseases such as psoriasis, rheumatoid arthritis, HIV), and high-risk ethnicity such as South Asian ancestry.
Coronary artery calcium scoring to improve risk stratification in moderate-risk patients for whom the benefits of statin therapy are uncertain.
Follow-up for adherence to medications and lifestyle and to assess adequacy of response.


American Association of Cardiovascular and Pulmonary Rehabilitation, American Academy of Physician Assistants, Association of Black Cardiologists, American College of Preventive Medicine, American Diabetes Association, American Geriatrics Society, American Pharmacists Association, American Society for Preventive Cardiology, National Lipid Association, and Preventive Cardiovascular Nurses Association

Back to HCB News

You Must Be Logged In To Post A Comment